Laidlaw Analyst Doubles Down on Nuvectis Citing NXP900 as True Value Driver; Reiterates $19 Price Target
Sponsored · Market Discovery ContentWall Street analyst sees strategic pivot as smart move, highlights NXP900’s impressive 90% target inhibition. Nuvectis’ increased focus and ability to divert greater resources and focus on NXP900 a major positive development given the potential of the drug candidate.
When biotech companies announce the end of a clinical program, Wall Street sometimes responds with downgrades or slashed price targets. That’s exactly why today’s research note from Laidlaw & Company stands out. Instead of backing away from Nuvectis Pharma (NASDAQ: NVCT) after the company announced it would discontinue NXP800 development in ovarian cancer, analyst Yale Jen did something unexpected: he called the news “actually positive” and kept his $19 price target firmly in place. That target, by the way, represents +170% upside from current levels around ~$7.
A Different Perspective on the News
Jen’s take is quite interesting. The wall street analyst sees disciplined management. “We always view an early attrition and re-direction of development programs to potentially maximize the potential of an asset a positive as it showcases management’s proper execution of pipeline management,” he wrote.
It’s a refreshingly mature perspective in a sector often dominated by binary thinking. Rather than throwing good money after a challenging indication, Nuvectis is cutting its losses and doubling down on its strongest asset.
The analyst’s math is straightforward: NXP800 in ovarian cancer was never meaningfully factored into the stock price anyway. “Given the Street sentiment that current NVCT valuation generally has not accounted for a success for NXP800, pausing this program development should have very limited impact.”
The Real Story: NXP900’s Knockout Data
But Jen’s optimism isn’t just about what Nuvectis stopped doing – it’s about what it’s shows with NXP900. The analyst specifically highlighted “the robust PD response of ~90% SRC kinase phosphorylation inhibition of >150mg/day NXP900.”
For context, that’s exceptional target engagement for a kinase inhibitor. Most oncology drugs consider themselves lucky to hit 70-80% target inhibition while maintaining tolerable side effects. Hitting 90% suggests NXP900 has the pharmacological horsepower to drive meaningful clinical responses.
The safety profile matters too. NXP900 reached doses up to 250mg daily without hitting dose-limiting toxicities – giving doctors plenty of room to optimize dosing for maximum benefit.
Why the $19 Target Still Makes Sense
Maintaining a price target after what some might view as disappointing news takes conviction. But Jen’s reasoning is sound: the investment thesis was never really about ovarian cancer.
NXP900’s opportunity in non-small cell lung cancer dwarfs anything NXP800 could have achieved in the ovarian setting. NSCLC represents a multi-billion dollar market with massive unmet need in the resistance setting – exactly where NXP900’s unique mechanism could shine.
Recent preclinical work has shown NXP900 can reverse resistance to drugs like osimertinib and alectinib, potentially breathing new life into therapies that have lost effectiveness. That’s not just a nice-to-have feature – it’s a potential game-changer in a market where resistance is the primary limiting factor.
Reading Between the Lines
What’s particularly interesting about Laidlaw’s note is the timing. The firm could have easily waited a few days, let the dust settle, and issued a more cautious take. Instead, they came out swinging on the same day as the announcement.
That suggests real conviction in the NXP900 story. When analysts maintain ambitious price targets in the face of what looks like bad news, it’s usually because they see something the broader market is missing.
In this case, it appears to be the distinction between tactical disappointment and strategic opportunity. Yes, NXP800 didn’t pan out in ovarian cancer. But that clears the deck for NXP900 to take center stage – and that might be exactly what long-term investors wanted to see happen.
What Happens Next
With Phase 1b trials for NXP900 expected to begin in the coming weeks, investors will likely be following it closely to see whether Laidlaw’s optimism is justified. The upcoming studies will test both single-agent activity in biomarker-selected patients and combination approaches with existing therapies.
Those results could validate the analyst’s thesis that NXP900’s “novel and differentiated approach” represents genuine value creation opportunity. Or they could prove that even sophisticated Wall Street analysis sometimes gets it wrong.
Time will tell whether that confidence pays off, but it’s hard to argue with the underlying logic: sometimes the best way forward is knowing what assets to focus on to maximize value generation.
Recent News Highlights from Nuvectis (Live Feed)
Disclaimer & Disclosure: This article is a form of paid promotional content/advertising. The Author, Wall Street Wire, has received compensation from Nuvectis Pharma Inc for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire are available wallstwire.ai/disclosures. We are not responsible for any price targets or market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. Readers are advised to refer to the full reports mentioned on various systems and the disclaimers/disclosures they may be subject to. This article has was not reviewed or approved by the issuer prior to publication and should not be considered an official communication by it.
The Block Brief
Get the next story before the market does.
Startup funding, venture capital and under-the-radar companies, in your inbox. Free.
